Patents by Inventor Rehan Aqil

Rehan Aqil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAP4K4 inhibitors
    Patent number: 11795169
    Abstract: This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 24, 2023
    Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Michael Schneider, Gary Newton, Katie Chapman, Trevor Perrior, Ashley Jarvis, Caroline Low, Rehan Aqil, Martin Fisher, Melanie Bayford, Nicholas Chapman, Nicholas Martin, Tifelle Reisinger, Gabriel Negoita-Giras, Lorna R. Fieldler
  • MAP4K4 INHIBITORS
    Publication number: 20200339583
    Abstract: This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I).
    Type: Application
    Filed: October 12, 2018
    Publication date: October 29, 2020
    Inventors: Michael SCHNEIDER, Gary NEWTON, Katie CHAPMAN, Trevor PERRIOR, Ashley JARVIS, Caroline LOW, Rehan AQIL, Martin FISHER, Melanie BAYFORD, Nicholas CHAPMAN, Nicholas MARTIN, Tifelle REISINGER, Gabriel NEGOITA-GIRAS, Lorna R. FIELDLER
  • 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
    Patent number: 9611223
    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: April 4, 2017
    Assignee: INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
    Inventors: Alan Ashworth, Christopher James Lord, Richard James Rowland Elliott, Dan Niculescu-Duvaz, Roderick Alan Porter, Rehan Aqil, Raymond John Boffey, Melanie Jayne Bayford, Stuart Firth-Clark, Anna Hopkins, Ashley Nicholas Jarvis, Trevor Robert Perrior, Philip Alan Skone, Rebekah Elisabeth Key
  • 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
    Publication number: 20160221953
    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
    Type: Application
    Filed: September 11, 2014
    Publication date: August 4, 2016
    Applicant: Institute of Cancer Research Royal Cancer Hospital (THE)
    Inventors: Alan ASHWORTH, Christopher James LORD, Richard James Rowland ELLIOT, Dan NICULESCU-DUVAZ, Roderick Alan PORTER, Rehan AQIL, Raymond John BOFFEY, Melanie Jayne BAYFORD, Stuart FIRTH-CLARK, Anna HOPKINS, Ashley Nicholas JARVIS, Trevor Robert PERRIOR, Philip Alan SKONE, Rebekah Elisabeth KEY
  • Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them
    Patent number: 8962609
    Abstract: C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKK? and/or TBK-1: in which: R1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R3 and R4 independently represents a hydrogen atom or a C1-4 alkyl group.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: February 24, 2015
    Assignee: Domainex Limited
    Inventors: Trevor Robert Perrior, Gary Karl Newton, Mark Richard Stewart, Rehan Aqil
  • PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20130267491
    Abstract: C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKK? and/or TBK-1: in which: R1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R3 and R4 independently represents a hydrogen atom or a C1-4 alkyl group.
    Type: Application
    Filed: July 18, 2011
    Publication date: October 10, 2013
    Applicant: DOMAINEX LIMITED
    Inventors: Trevor Robert Perrior, Gary Karl Newton, Mark Richard Stewart, Rehan Aqil
  • Therapeutic delivery of carbon monoxide
    Patent number: 8389572
    Abstract: Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: March 5, 2013
    Assignee: hemoCORM Limited
    Inventors: Roberto Angelo Motterlini, Brian Ernest Mann, Tony Richard Johnson, David Alistair Scapens, Rehan Aqil, Trevor Perrior
  • THERAPEUTIC DELIVERY OF CARBON MONOXIDE
    Publication number: 20110015263
    Abstract: Compounds, pharmaceutical compositions and methods for the therapeutic delivery of carbon monoxide to humans and other mammals that employ transition metal complexes having at least a substituted cyclopentadienyl, indenyl or fluorenyl ligand and two or more carbonyl ligands.
    Type: Application
    Filed: January 23, 2007
    Publication date: January 20, 2011
    Inventors: Roberto Angelo Motterlini, Brian Ernest Mann, Tony Richard Johnson, David Alistair Scapens, Rehan Aqil, Trevor Perrior